Search Results - "Johnson, P. W. M."

Pharmacological inhibitors of NF-κB accelerate apoptosis in chronic lymphocytic leukaemia cells by PICKERING, B. M, DE MEL, S, JOHNSON, P. W. M, STEVENSON, F. K, PACKHAM, G, LEE, M, HOWELL, M, HABENS, F, DALLMAN, C. L, NEVILLE, L. A, POTTER, K. N, MANN, J, MANN, D. A

“…Nuclear factor-kappaB (NF-κB) is a transcription factor that plays a critical role in the inappropriate survival of various types of malignant cells. Chronic…”
Get full text

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? by Nolan, L, Johnson, P W M, Ganesan, A, Packham, G, Crabb, S J

“…Histone deacetylase inhibitors have progressed rapidly from the laboratory to clinical testing. This review highlights the promising data for their combination…”
Get full text

25 YEARS OF ANTIBODY TREATMENTS FOR LYMPHOMA by Johnson, P. M. W.

Get full text

Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519) by Owadally, W.S., Sydes, M.R., Radford, J.A., Hancock, B.W., Cullen, M.H., Stenning, S.P., Johnson, P.W.M.

“…This analysis was undertaken to assess the relationship between the dose intensity (DI) of initial chemotherapy and outcome in a large cohort of patients with…”
Get full text

Differential regulation of cell survival by CD40 by DALLMAN, C, JOHNSON, P. W. M, PACKHAM, G

“…The CD40 cell surface receptor is required for normal function of the immune system and is a positive regulator of cell survival for normal B-lymphocytes…”
Get full text

The Emerging Role Of Radioimmunotherapy In Haematological Malignancies by Illidge, T. M., Johnson, P. W. M.

Get full text

New targets for lymphoma treatment by Johnson, P. W. M.

Get full text

Primary mediastinal B-cell lymphoma by Boleti, E, Johnson, P W M

“…Primary mediastinal B‐cell lymphoma (PMBCL) is a sub‐type of the heterogeneous diffuse large B‐cell lymphoma category, and comprises approximately 5% of all…”
Get full text

Rituximab: mechanisms and applications by JOHNSON, P. W. M, GLENNIE, M. J

Get full text

A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPY by Davies, A. J., Zucca, E., Ceriani, L., Kryachok, I., Ciccone, G., Botto, B., Balzarotti, M., Tucci, A., Rusconi, C., Usai, S. V., Pennese, E., Arcaini, L., Dabrowska‐Iwanicka, A., Ferreri, A. J. M., Merli, F., Zhao, W., Hodgson, D., Rigacci, L., Cellini, C., Stelitano, C., Zaja, F., Guarini, A., Ionescu, C., Spina, M., Fossa, A., Cwynarski, K., Mikhaeel, N G., Jerkeman, M., Janikova, A., Hüttmann, A., Da Silva, M. Gomes, Stevens, D., Barrington, S., Malkowski, B., Metser, U., Versari, A., Chauvie, S., Ricardi, U., Bagni, O., Di Rocco, A., Gospodarowicz, M., Cavalli, F., Johnson, P. W. M., Martelli, M.

Get full text

Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event? by McCann, K J, Johnson, P W M, Stevenson, F K, Ottensmeier, C H

Get full text

Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytes by Habens, F, Lapham, A S, Dallman, C L, Pickering, B M, Michels, J, Marcusson, E G, Johnson, P W M, Packham, G

“…Bcl-X(L) is a Bcl-2-related survival protein that is essential for normal development. Bcl-X(L) expression is rapidly induced by a wide range of survival…”
Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Johnson, P M W

Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Shipp, M A

Get full text

Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study by Johnson, P. W. M., Swinbank, K., MacLennan, S., Colomer, D., Debuire, B., Diss, T., Gabert, J., Gupta, R. K., Haynes, A., Kneba, M., Lee, M. S., Macintyre, E., Mensink, E., Moos, M., Morgan, G. J., Neri, A., Johnson, A., Reato, G., Salles, G., van't Veer, M. B., Zehnder, J. L., Zucca, E., Selby, P. J., Cotter, F. E.

“…Background: The capacity of the polymerase chain reaction (PCR) to detect very low numbers of cells bearing a t(14;18) translocation has led to its application…”
Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Ceriani, L, Milan, L, Cascione, L, Di Rocco, A, Kryachok, I, Davies, A J, Stathis, A, Johnson, P W M, Ciccone, G, Martelli, M, Zucca, E

Get full text

A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer by JOHNSON, P. W. M, MUERS, M. F, PEAKE, M. D, POULTER, K. M, GURNEY, E. M, NAPP, V, HEPBURN, P. M, BROWN, J. M

“…A randomized trial was conducted to determine whether administration of Amifostine with chemotherapy for small cell lung cancer could decrease the toxicity. 84…”
Get full text

A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPY by Davies, A. J., Zucca, E., Ceriani, L., Kryachok, I., Ciccone, G., Botto, B., Balzarotti, M., Tucci, A., Rusconi, C., Usai, S. V., Pennese, E., Arcaini, L., Dabrowska‐Iwanicka, A., Ferreri, A. J. M., Merli, F., Zhao, W., Hodgson, D., Rigacci, L., Cellini, C., Stelitano, C., Zaja, F., Guarini, A., Ionescu, C., Spina, M., Fossa, A., Cwynarski, K., Mikhaeel, N G., Jerkeman, M., Janikova, A., Hüttmann, A., Silva, M. Gomes, Stevens, D., Barrington, S., Malkowski, B., Metser, U., Versari, A., Chauvie, S., Ricardi, U., Bagni, O., Di Rocco, A., Gospodarowicz, M., Cavalli, F., Johnson, P. W. M., Martelli, M.

Get full text

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia by Agathocleous, Agathoclis, Rohatiner, Ama, Rule, Simon, Hunter, Hannah, Kerr, Jonathan Paul, Neeson, Susan M., Matthews, Janet, Strauss, Sandra, Montoto, Silvia, Johnson, Peter, Radford, John, Lister, Andrew

“…Summary The combination of bortezomib and rituximab was evaluated in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL) and Waldenström…”
Get full text

The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial by Rule, Simon, Smith, Paul, Johnson, Peter W M, Bolam, Simon, Follows, George, Gambell, Joanne, Hillmen, Peter, Jack, Andrew, Johnson, Stephen, Kirkwood, Amy A, Kruger, Anton, Pocock, Christopher, Seymour, John F, Toncheva, Milena, Walewski, Jan, Linch, David

“…Mantle cell lymphoma is an incurable and generally aggressive lymphoma that is more common in elderly patients. Whilst a number of different chemotherapeutic…”
Get full text